Alnylam finds belly fat gene and drug target in UK Biobank study
pharmaphorum
JULY 28, 2022
Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease. The post Alnylam finds belly fat gene and drug target in UK Biobank study appeared first on.
52 
Let's personalize your content